Applied DNA products and services offer forensic, high-value differentiation for Schreiner MediPharm’s customers to secure supply chains

STONY BROOK, N.Y. August 7, 2019 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”, the “Company”), a leader in PCR-based DNA manufacturing for product authenticity and traceability solutions, announced today the signing of a Master Services Agreement with Germany-based Schreiner Group, an award-winning 68-year old company specializing in innovative, functional labels and  integrated security solutions across many industries, including the Pharmaceutical Industry through its Schreiner MediPharm business unit.

Applied DNA will supply its SigNature^® DNA forensic molecular tag with Beacon^® screening feature for Schreiner MediPharm’s high-end security label portfolio within the Pharmaceutical Industry for product and brand protection of its customers’ supply chains. Schreiner MediPharm will also provide authentication services to its customers using the Applied DNA SigNify^® portable DNA readers now in use at the Schreiner ProSecure competence center, providing security technologies and services to Schreiner MediPharm as well as Schreiner Group’s other business units.

In a joint development, SigNature DNA and Beacon were integrated in Schreiner MediPharm’s security label concepts and processes. These were validated over the last 18 months during which time the labels have undergone exhaustive environmental and reliability testing by both partners.

Dr. James Hayward, President and CEO of Applied DNA, said, “Schreiner MediPharm is an industry leader who brings top notch science and engineering to its pharmaceutical label portfolio with a spirit of innovation. Given the reported and continued high incidence rate of counterfeits within the pharmaceutical supply chain, we firmly believe the forensic SigNature DNA-protected labels will be of significant value in ensuring authentic medicines reach patients.”

Dr. Nadine Lampka, Product Manager Pharma-Security at Schreiner MediPharm, said, “Integrating SigNature DNA in combination with Beacon in our functional pharma labels will be setting a new security standard in the pharmaceutical industry. DNA-Secure is extremely robust, flexible to integrate and allows both, a quick in-field test and an ultimate forensic proof in the lab. It provides excellent value for money and complements our portfolio of integrated authentication features on the high-security end.”

About Schreiner Group
Schreiner Group GmbH & Co. KG is an internationally active German family-owned business operating in the printing and film-converting industry. The company offers tailored products, solutions and services for the pharmaceutical and medical device industry, logistics, mechanical engineering, the electronics and automotive industries. In addition, Schreiner Group’s customer base includes banks and government agencies. The product portfolio encompasses innovative specialty labels, including self-adhesive functional components, RFID labels, printed electronics, and security solutions for product, brand and document protection. Schreiner Group employs more than 1,100 people around the globe, generating annual sales of more than 180 million euros, and is headquartered in Oberschleissheim near Munich (Germany). Schreiner Group’s high-tech labels are also produced in Blauvelt (New York, USA) and in Fengpu (Shanghai, China). The company’s facilities extend across a total area of 72,000 square meters.For more information, visit schreiner-group.com.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, limited market acceptance , the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, ability to maintain its NASDAQ listing and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018 and our subsequent quarterly reports on Form 10-Q filed on February 7, 2019 and May 9, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
Media contact: Meryl Rader, 781-639-4924, meryl@cgprpublicrelations.com
Program contacts: Tony Benson, +44 (0) 7552 429341, tony.benson@adnas.com

STONY BROOK, N.Y., August 6, 2019 – Applied DNA Sciences, Inc. (NASDAQ: APDN), announced today it plans to release financial results for its fiscal 2019 third quarter ended June 30, 2019 after market close on Tuesday, August 13, 2019. In conjunction with the release, the Company has scheduled a conference call at 4:30 p.m. Eastern Time that will also be broadcast live over the Internet.

What: Applied DNA’s Fiscal 2019 Third Quarter Financial Results Conference Call

When: Tuesday, August 13, 2019, at 4:30 p.m. Eastern Time

Where: Via phone by dialing +1 844-887-9402 or +1 412-317-6798 and ask to join the Applied DNA call;via webcast.

A telephonic replay of the conference call will be available for one day and may be accessed by calling +1 877-344-7529 or +1 412-317-0088 with the passcode 10133063. The webcast will be archived within the ‘Events and Presentations’ portion of the ‘Investors’ page to the company’s website.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.Common stock listed on NASDAQ under the symbol ‘APDN’ and warrants are listed under the symbol ‘APDNW’.

Forward Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its ability to repay the Notes if not converted, history of net losses, limited financial resources, limited market acceptance, ability to maintain its NASDAQ listing and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018 and our subsequent quarterly reports on Form 10-Q filed on February 7, 2019 and May 9, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com

Amendments fortify the Agreement, allow revenue recognition, and strengthen the Applied DNA Balance Sheet

STONY BROOK, N.Y., August 5, 2019 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based (Polymerase Chain Reaction) DNA manufacturing for product authenticity and traceability solutions, today announced that the Company and TheraCann International Benchmark Corporation (“TheraCann”) have signed a non-binding term sheet (the “Term Sheet”) outlining agreed-upon amendments to the exclusive licensing and cooperation agreement signed March 28, 2019 between the parties (the “Agreement”). The Term Sheet is expected to be followed by definitive contractual amendments.

Under the Term Sheet, the parties agreed to amend the Agreement to provide Applied DNA with $4M in TheraCann convertible preferred stock and a $1M convertible promissory note in exchange for Applied DNA’s waiver of $4M in cash payments due from TheraCann on or before August 15, 2019.  Recognition of $4 million in revenue by Applied DNA (unaudited) will take effect with the signing of the definitive agreement(s), expected in the current quarter.

“The contractual amendments will be mutually beneficial and is a testimony to the strength of our relationship with TheraCann,” stated Dr. James Hayward, president and CEO of Applied DNA. “The amendments will strengthen the Applied DNA balance sheet as well as increase Shareholder Equity as we enter the Nasdaq delisting appeals process, and at the same time, allow TheraCann to remain in compliance with the terms of Agreement as it pursues listing on the TSX Venture Exchange.”

“Our commercial opportunities are steadily strengthening and combined with the contractual amendments will enable our rapid growth for our current and future shareholders,” said Jason Warnock, CEO of TheraCann.

Applied DNA notes that the Term Sheet is a preliminary and non-binding document. All terms contemplated therein will only become operative if definitive contractual amendments are signed. It is possible that no definitive contractual amendments will be reached, or, the amendments may differ from those described above.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

About TheraCann
Founded in 2004, TheraCann International Benchmark Corporation offers a one-stop, full-service solution for the International cannabis marketplace. TheraCann provides business, technology and industry experts who apply advanced technology and help clients design, build and run their cannabis businesses. Integrating nearly 3.5 million square feet of cannabis operations and the successful launch of groundbreaking Enterprise Resource Planning (ERP) software, Aeroponic cultivation systems and patented genetic tracking and diversion prevention systems, TheraCann provides cannabis-related businesses with solutions to fit their regulatory requirements.

More information about TheraCann is available at www.theracanncorp.com. Follow us on Twitter or Linkedin.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its ability to repay the Notes if not converted, history of net losses, limited financial resources, limited market acceptance, ability to maintain its NASDAQ listing, shifting enforcement priorities of US federal laws relating to cannabis, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018 and our subsequent quarterly reports on Form 10-Q filed on February 7, 2019 and May 9, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

For Applied DNA: investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com

Don’t be so sure your Apple product is the real thing.

A Chinese national living in the U.S. on a student visa smuggled more than 40,000 electronic devices and accessories, including iPads and iPhones, from China into the U.S. before getting apprehended, according to an announcement made this week by the by U.S. Immigration and Customs Enforcement’s Homeland Security Investigations (HSI) division, the Department of Justice said.

“Online purchasing of consumer electronics from sites other than the manufacturer amplifies the opportunity for counterfeits,” James A. Hayward, Ph.D., Chairman, President & CEO of Stony Brook, NY-based Applied DNA Sciences, told Fox News.  Applied DNA secures supply chains for electronic components using unique DNA molecular tags that the company designs and manufactures.

But Hayward adds that it’s “a buying pattern that is hard to break.” Consumers often opt for online retailers that sell devices at a lower price than the manufacturer.

Existing Notes Amended as Part of Plan to Strengthen Balance Sheet and Regain Nasdaq Listing Standards Compliance

STONY BROOK, N.Y., July 17, 2019 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based (Polymerase Chain Reaction) DNA manufacturing for product authenticity and traceability solutions, today announced that it closed on $1.5 million in gross proceeds in secured convertible notes (the “July 2019 Notes”) by way of non-brokered private placement with an accredited investor, Dillon Hill Capital, LLC. Under the terms of the July 2019 Notes, Dillon Hill retains the option to make additional investments in the Notes over the next 90 calendar days. The Company expects to use the net proceeds for general corporate purposes.

Simultaneously and as part of the Company’s plan to regain NASDAQ listing standards compliance, Applied DNA announced it has amended the terms of its secured convertible notes issued on August 31, 2018 and November 29, 2018 (“the Existing Notes”) to, among other amendments, reduce the conversion price of the Existing Notes to $0.54 to facilitate their conversion into equity.

“We appreciate the investment and support of our new and existing Notes holders,” stated Dr. James Hayward. “We remain focused on growth for the balance of fiscal 2019.”

The aggregate outstanding principal amount of the July 2019 Notes and Existing Notes is $3.8 million with a maturity date of November 28, 2021 for all notes. For more information on the July 2019 Notes and the amendments to the Existing Notes, please see the Company’s filing with the Securities and Exchange Commission.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its ability to repay the Notes if not converted, history of net losses, limited financial resources, limited market acceptance, ability to maintain its NASDAQ listing and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018 and our subsequent quarterly reports on Form 10-Q filed on February 7, 2019 and May 9, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

For Applied DNA: Investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com

BY LEXIE SACHS, GOOD HOUSEKEEPING INSTITUTE | Jul 12, 2019

Quality sheets are the key to a good night’s sleep. After all, it’s impossible to get comfortable if you’re wrapped up in scratchy material or a fabric that makes you feel hot. And since nothing’s worse than investing in bedding that constantly needs to be replaced, you’ll also want ones that are long-lasting. The good news: We’ve tested dozens of sheet sets and have found the ones you’ll love sleeping in.

CertainT platform from Applied DNA Sciences provides supply chain transparency

New York – Loftex sourced-verified towels made from cotton and post-consumer recycled poly have rolled out to retail.

The towels offer transparency through the use of the CertainT platform. Developed by Applied DNA Sciences, the platform is used to tag, test and track materials within a supply chain to verify authenticity.“

Consumers expect transparency in the products they choose to purchase, especially ones that claim to use recycled content. Smart retailers have committed to sustainability goals and our new eco-friendly performance towels help them get there,” said Charles Gaenslen, CEO of Loftex Home.

Aficionados of Montblanc luxury goods will soon be able to ensure the authenticity of their pieces. Montblanc-Simplo GMBH, parent of the Montblanc brand, has signed a five-year agreement with Applied DNA Sciences Inc., a specialist in DNA-based product authenticity and traceability solutions, to provide unique SigNature DNA marks for individual Montblanc clients.

Orders Reflect Growing Interest across the Biotech Industry for Bacteria-Free, Plasmid-Free Therapies

STONY BROOK, NY. July 1, 2019 – LineaRx, Inc., a wholly-owned subsidiary of Applied DNA Sciences, Inc. (“Applied DNA or the Company,” NASDAQ: APDN), announced today that it has received multiple purchase orders, from several major developers of gene and cell therapies, for its proprietary and patented large-scale, polymerase-chain-reaction (PCR)-produced linear DNA. LineaRx believes this momentum reflects increasing interest across the biotech industry to pursue a cleaner, higher-performing alternative to plasmid DNAs that are produced by fermentation in bacteria.

Under these Phase 1 CRO (Contract Research Organization) agreements, the performance of linear DNA will be benchmarked by criteria such as gene expression, and cell viability, against existing data from DNA produced using plasmids. LineaRx will also optimize, produce, and purify the products as required for testing both in vitro and in vivo by our customers. Upon successful benchmarking, LineaRx expects these customers will proceed to Phase 2 studies that leverage additional LineaRx intellectual property to enhance expression levels or expression lifetimes to drive greater therapeutic performance, while optimizing costs.

“In a number of completed studies, our linear DNA has met or exceeded the performance of plasmid DNA, as measured by gene expression, cell viability, and immunogenicity,” stated Dr. James Hayward, president and CEO of LineaRx. “These new Phase 1 CRO studies will seek to establish the performance of our linear DNA with several significant biotech companies focused on gene and cell therapies, including those focused on adoptive cellular therapies as well as RNA-based therapeutics. This increasing interest that encompasses a broad spectrum of industry players is an early, yet important, endorsement of our view that our proprietary PCR technology offers the potential for improved outcomes relative to current plasmid and viral-vector production technologies.”

To produce the quantities of DNA required for therapeutics, plasmid DNA is grown in bacteria and requires a costly purification process in an attempt to remove bacterial and non-target plasmid DNA, as well as bacterial toxins, before the purified DNA is used. It is commonly known that residual unintended DNA may still be present worrisome concentrations in the final product. LineaRx intends to eliminate the risk associated with the presence of bacterial or unintended plasmid DNA in current therapies via its expertise in the design, manufacture and chemical modification of DNA by large scale PCR.

“We attribute the increase in CRO orders, from marquis companies, to the growing desire to eliminate the risk associated with the presence of bacterial or unintended plasmid DNA in their therapies,” added Hayward. “We expect these CRO projects will evolve to CMO (Contract Manufacturing Organization) orders as some of these customers, once through their pre-clinical work, will bring linear DNA-based therapies to clinical trial within the next 18 months.”

About LineaRx
LineaRx seeks to commercialize the biotherapeutic value of Applied DNA Sciences’ deep expertise and experience in the design, manufacture and chemical modification of DNA by large scale polymerase chain reaction (“PCR”). Linear DNA is a form of DNA distinct from the circular form of DNA most commonly produced in plasmids and grown in bacteria.  Plasmids are extrachromosomal DNA found in bacteria and are associated with the genes for antibiotic resistance which are often exchanged between bacteria and consequentially, are seen by many to embody a serious threat to global health. In addition, many nucleic acid-based therapies also rely on viral vectors for efficient transfection and expression of plasmid DNA. These viral vectors carry additional nontrivial risks and are extremely time consuming and expensive to manufacture.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, limited market acceptance , the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, ability to maintain its NASDAQ listing and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018 and our subsequent quarterly reports on Form 10-Q filed on February 7, 2019 and May 9, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
program contact: Brian Viscount, 631-240-8877, brian.viscount@adnas.com